올란자핀-발프로에이트 병용 치료 시 발생한 가역적 호중구 감소증 2예

참고문헌 (24)

1. Alvir JM, "Clozapine-induced agranulocytosis. Incidence and risk factors in the United States", N Engl J Med, 329, pp.162~167 (1993)
2. Casey DE, "The relationship of pharmacology to side effects", J Clin Psychiatry, 58(Supple 10), pp.55~62 (1997)
3. Beasley CM, "Safety of olanzapine", J Clin Psychiatry, 58(Suppl 10), pp.13~17 (1997)
4. Thinn SS, "Reversible delayed onset olanzapine-associated leucopenia and neutropenia in a clozapinenaive patient on concomitant depot antipsychotic", J Clin Psychopharmacol, 27, pp.394~395 (2007)
5. Cordes J, "Reversible neutropenia during treatment with olanzapine: three case reports", World J Biol Psychiatry, 5, pp.230~234 (2004)
6. Su JA, "Olanzapine-induced agranulocytosis in systemic lupus erythematosus: a case report", Gen Hosp Psychiatry, 29, pp.75~77 (2007)
7. Stip E, "Fatal agranulocytosis: the use of olanzapine in a patient with schizophrenia and myelodysplasia", Prog Neuropsychopharmacol Biol Psychiatry, 31, pp.297~300 (2007)
8. Sayin A, "Prolongation of clozapine-induced leucopenia with olanzapine treatment", Prog Neuropsychopharmacol Biol Psychiatry, 30, pp.958~959 (2006)
9. Shankar BR, "Quetiapine-induced leukopenia and thrombocytopenia", Psychosomatics, 486, pp.530~531 (2007)
10. Burckart GJ, "Neutropenia following acute chlorpromazine ingestion", Clin Toxicol, 18, pp.797~801 (1981)
11. Tohen M, "Blood dyscrasias with carbamazepine and valproate: a pharmacoepidemiological study of 2,228 patients at risk", Am J Psychiatry, 152, pp.413~418 (1995)
12. Teter CJ, "Olanzapine-induced neutropeina in patients with history of clozapine treatment: two case reports from a state psychiatric institution", J Clin Psychiatry, 61, pp.872~873 (2000)
13. Thangadurai P, "Reversible neutropenia with olanzapine following clozapine-induced neutropenia", Am J Psychiatry, 163, pp.1298~ (2006)
14. Duggal HS, "Psychotropic drug-induced neutropenia", Drugs Today (Barc), 41, pp.517~526 (2005)
15. Steinwachs A, "Two cases of olanzapine-induced reversible neutropenia", Pharmacopsychiatry, 32, pp.154~156 (1999)
16. Rahman A, "Evaluating the incidence of leukopenia and neutropenia with valproate, quetiapine, or the combination in children and adolescents", Ann Pharmacother, 43, pp.822~830 (2009)
17. Duggal HS, "Olanzapine-induced neutropeina: mechanism and treatment", J Clin Psychopharmacol, 24, pp.234~235 (2004)
18. Pantelis C, "Increased risk of neutropaenia and agranulocytosis with sodium valproate used adjunctively with clozapine", Aust N Z J Psychiatry, 35, pp.544~545 (2001)
19. Liu ZC, "Clozapine is oxidized by activated human neutrophils to a reactive nitrenium ion that irreversibly binds to the cells", J Pharmacol Exp Ther, 275, pp.1476~1483 (1995)
20. Gardner I, "A comparison of the covalent binding of clozapine and olanzapine to human neutrophils in vitro and in vivo", Mol Pharmacol, 53, pp.999~1008 (1998)
21. Uetrecht JP, "Oxidation of aminopyrine by hypochlorite to a reactive dication: possible implications for aminopyrine-induced agranulocytosis", Chem Res Toxicol, 8, pp.226~233 (1995)
22. Waldhauser L, "Oxidation of propilthiouracil to reactive metabolites by activated neutrofils. Implications for agranulocytosis", Drug Metab Dispos, 19, pp.354~359 (1991)
23. Gardner I, "A comparison of the oxidation of clozapine and olanzapine to reactive metabolites and the toxicity of these metabolites to human leukocytes", Mol Pharmacol, 53, pp.991~998 (1998)
24. Dettling M, "Genetic determinants of drug-induced agranulocytosis: potential risk of olanzapine?", Pharmacopsychiatry, 32, pp.110~112 (1999)

관련 논문AI추천